Market capitalization | DKK51.82b |
Enterprise Value | DKK43.74b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 568.97 |
P/S ratio (TTM) P/S ratio | 674.12 |
P/B ratio (TTM) P/B ratio | 5.83 |
Revenue growth (TTM) Revenue growth | -77.62% |
Revenue (TTM) Revenue | DKK76.87m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a Zealand Pharma forecast:
12 Analysts have issued a Zealand Pharma forecast:
Sep '24 |
+/-
%
|
||
Revenue | 77 77 |
78%
78%
|
|
Gross Profit | 55 55 |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -1,112 -1,112 |
114%
114%
|
Net Profit | -1,053 -1,053 |
38%
38%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Head office | Denmark |
CEO | Adam Steensberg |
Employees | 253 |
Founded | 1997 |
Website | www.zealandpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.